Trial · NCT00842608

Pharmacological Management of Delirium

NCT00842608, Not applicable, Completed, Indiana University; results first posted 2017-03-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Pharmacological Management of Delirium. Trials, record NCT00842608. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00842608

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Pharmacological Management of Delirium
NCT number: NCT00842608
Status: Completed
Phases: Not applicable
Enrollment: 551 participants, actual
Lead sponsor: Indiana University
Conditions: Delirium, Cognitive Impairment
Interventions: Reduced exposure to anticholinergics, Reduced exposure to benzodiazepines, Haloperidol, Usual care
First posted: 2009-02-12
Last updated: 2018-08-17
Results first posted: 2017-03-24

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame
Primary	Days Free of Delirium and Coma	Admission through day 8 of stay
Secondary	Hospital Length of Stay Post Randomization	Participants were followed for the duration of hospital stay, an average of 11 days
Secondary	Mortality	ICU, in-hospital, 30-days post hospitalization

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Days Free of Delirium and Coma	Admission through day 8 of stay	days	MEDIAN
SECONDARY	Hospital Length of Stay Post Randomization	Participants were followed for the duration of hospital stay, an average of 11 days	days	MEAN
SECONDARY	Mortality	ICU, in-hospital, 30-days post hospitalization	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Days Free of Delirium and Coma	Haloperidol Eligible Intervention	4	Inter-Quartile Range 2 to 7	days
Days Free of Delirium and Coma	Haloperidol Eligible Usual Care	5	Inter-Quartile Range 1 to 7	days
Days Free of Delirium and Coma	Haldol-Ineligible Arm	4	Inter-Quartile Range 1 to 7	days
Days Free of Delirium and Coma	Haldol Ineligible Usual Care	5	Inter-Quartile Range 2 to 7	days
Hospital Length of Stay Post Randomization	Haloperidol Eligible Intervention	20.2	Standard Deviation 33.5	days
Hospital Length of Stay Post Randomization	Haloperidol Eligible Usual Care	18.6	Standard Deviation 31.6	days
Hospital Length of Stay Post Randomization	Haldol-Ineligible Arm	18.8	Standard Deviation 17.1	days
Hospital Length of Stay Post Randomization	Haldol Ineligible Usual Care	14.9	Standard Deviation 11.8	days
Mortality	Haloperidol Eligible Intervention	20		Participants
Mortality	Haloperidol Eligible Usual Care	32		Participants

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Haloperidol Eligible Intervention	174
Overall Study	STARTED	Haloperidol Eligible Usual Care	177
Overall Study	STARTED	Haldol-Ineligible Arm	99
Overall Study	STARTED	Haldol Ineligible Usual Care	101
Overall Study	COMPLETED	Haloperidol Eligible Intervention	170
Overall Study	COMPLETED	Haloperidol Eligible Usual Care	176
Overall Study	COMPLETED	Haldol-Ineligible Arm	99
Overall Study	COMPLETED	Haldol Ineligible Usual Care	100
Overall Study	NOT COMPLETED	Haloperidol Eligible Intervention	4
Overall Study	NOT COMPLETED	Haloperidol Eligible Usual Care	1

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events48

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	General Events	General disorders	Haloperidol Eligible Intervention	87	174
other	General Events	General disorders	Haloperidol Eligible Usual Care	82	177
other	General Events	General disorders	Haldol-Ineligible Arm	63	99
other	General Events	General disorders	Haldol Ineligible Usual Care	59	101
serious	Patients with CNS	Nervous system disorders	Haloperidol Eligible Intervention	5	174
serious	Patients with CNS	Nervous system disorders	Haloperidol Eligible Usual Care	7	177
serious	Patients with CNS	Nervous system disorders	Haldol-Ineligible Arm	4	99
serious	Patients with CNS	Nervous system disorders	Haldol Ineligible Usual Care	2	101
serious	Patients with Cardiovascular	Cardiac disorders	Haloperidol Eligible Intervention	14	174
serious	Patients with Cardiovascular	Cardiac disorders	Haloperidol Eligible Usual Care	20	177

1 to 10 of 48Source ClinicalTrials.gov

See all 48 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Haloperidol Eligible Intervention
Total, all-cause mortality	Haloperidol Eligible Usual Care
Total, all-cause mortality	Haldol-Ineligible Arm
Total, all-cause mortality	Haldol Ineligible Usual Care
Total, other adverse events	Haloperidol Eligible Intervention	87	174
Total, other adverse events	Haloperidol Eligible Usual Care	82	177
Total, other adverse events	Haldol-Ineligible Arm	63	99
Total, other adverse events	Haldol Ineligible Usual Care	59	101
Total, serious adverse events	Haloperidol Eligible Intervention	45	174
Total, serious adverse events	Haloperidol Eligible Usual Care	57	177

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers5

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
21645330	DERIVED	PubMed
30681720	DERIVED	PubMed
32383964	DERIVED	PubMed
36002562	DERIVED	PubMed
37589315	DERIVED	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01AG034205	Pharmacological Management of Delirium	BOUSTANI, MALAZ	INDIANA UNIVERSITY INDIANAPOLIS	NATIONAL INSTITUTE ON AGING	2010 to 2014

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00842608

GET https://conductscience.org/api/trials/v1/NCT00842608/events?page=2

API reference For AI assistants